Sam Chun Dang Pharm countered that "the sale of the largest shareholder is groundless"

Reporter Kim Jisun / approved : 2024-04-05 03:07:22
  • -
  • +
  • 인쇄

 

[Alpha Biz= Reporter Kim Jisun] Sam Chun Dang Pharm's share price plunged recently due to unfavorable rumors circulating in the market, suggesting a legal response to the distributor.

According to the Korea Exchange on the 4th, Sam Chun Dang Pharm closed at 111,400 won on the KOSDAQ market. The stock price plunged 20% in three trading days from KRW 140,700 on the 1st.

There is a rumor that spread in the market behind the plunge in Sam Chun Dang Pharm's stock price. It is a negative rumor related to the core valuation business, the Ilia biosimilar, and the sale of the largest shareholder.

The largest shareholder of Sam Chun Dang Pharm is Sohwa (30.7%). Yoon Dae-in, chairman of Samcheondang Pharmaceutical, holds 6.9%. The largest shareholder of unlisted companies is Chairman Yoon (72.22%).

 

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

주요기사

Hyundai Motor Group Restores Vehicle Control Apps After 10-Hour Outage2025.09.18
HMM Completes Share Buyback Worth KRW 2.14 Trillion2025.09.18
Gyeonggi Police Arrest Two Chinese Nationals Over KT Mobile Payment Hacking Scheme2025.09.18
Financial Services Commission Imposes ₩3.66 Billion in Fines on STX and STX Marine Service for Accounting Violations Related to Overseas Litigation2025.09.18
Kakao Union Protests Mandatory Forensic Consent, Demands Immediate Withdrawal2025.09.18
뉴스댓글 >